Gold nanoparticles to improve HIV drug delivery

Papers of special note have been highlighted as: • of interest

References

• 1 Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131(2), 81–87 (1999).
  Medline CASGoogle Scholar
• 2 Yazdanpanah Y, Fagard C, Descamps D et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin. Inf. Dis. 49(9), 1441–1449 (2009).
  Medline CASGoogle Scholar
• 3 Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761–769 (2007).• Comprehensive review of the state of the art in nanoparticle use for therapeutics.
  MedlineGoogle Scholar
• 4 Mahajan SD, Aalinkeel R, Law WC et al. Anti-HIV-1 nanotherapeutics: promises and challenges for the future. Int. J. Nanomedicine 7, 5301–5314 (2012).
  Medline CASGoogle Scholar
• 5 Nowacek A, Mcmillan J, Miller R, Anderson A, Rabinow B, Gendelman H. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroaids therapeutics. J. Neuroimmune Pharmacol. 5(4), 592–601 (2010).• Interesting approach of antiretroviral nanoformulations using a cell-based delivery system to improve distribution.
  MedlineGoogle Scholar
• 6 Shibata A, Pham A, Belshan M et al. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. AIDS Res. Hum. Retroviruses 29(5), 746–754 (2013).
  Medline CASGoogle Scholar
• 7 Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312(5776), 1027–1030 (2006).
  Medline CASGoogle Scholar
• 8 Thaxton CS, Georganopoulou DG, Mirkin CA. Gold nanoparticle probes for the detection of nucleic acid targets. Clin. Chim. Acta 363(1–2), 120–126 (2006).
  Medline CASGoogle Scholar
• 9 Loo C, Hirsch L, Lee M-H et al. Gold nanoshell bioconjugates for molecular imaging in living cells. Opt. Lett. 30(9), 1012–1014 (2005).
  Medline CASGoogle Scholar
• 10 Gibson JD, Khanal BP, Zubarev ER. Paclitaxel-functionalized gold nanoparticles. J. Am. Chem. Soc. 129(37), 11653–11661 (2007).
  Medline CASGoogle Scholar
• 11 Libutti SK, Paciotti GF, Byrnes AA et al. Phase I and pharmacokinetic studies of CYT-6091, a novel pegylated colloidal gold-rh TNF nanomedicine. Clin. Cancer Res. 16(24), 6139–6149 (2010).
  Medline CASGoogle Scholar
• 12 Bresee J, Maier KE, Melander C, Feldheim DL. Identification of antibiotics using small molecule variable ligand display on gold nanoparticles. Chem. Comm. 46, 7516–7518 (2010).
  Medline CASGoogle Scholar
• 13 Bowman M-C, Ballard TE, Ackerson CJ, Feldheim DL, Margolis DM, Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 130(22), 6896–6897 (2008).• Reports the use of the same gold nanoparticles of the present study conjugated with a different antiretroviral drug.
  Medline CASGoogle Scholar
• 14 Simpson CA, Huffman BJ, Gerdon AE, Cliffel DE. Unexpected toxicity of monolayer protected gold clusters eliminated by PEG-thiol place exchange reactions. Chem. Res. Toxicol. 23(10), 1608–1616 (2010).
  Medline CASGoogle Scholar
• 15 Simpson CA, Salleng KJ, Cliffel DE, Feldheim DL. In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomedicine 9(2), 257–263 (2013).
  Medline CASGoogle Scholar
• 16 Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6(4), 662–668 (2006).• Studies the importance of gold nanoparticles’ size in their ability to enter cells.
  Medline CASGoogle Scholar
• 17 Kim JA, Aberg C, Salvati A, Dawson KA. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nano 7(1), 62–68 (2012).
  CASGoogle Scholar
• 18 Tkachenko AG, Xie H, Liu Y et al. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 15(3), 482–490 (2004).
  Medline CASGoogle Scholar
• 19 Baumann D, Hofmann D, Nullmeier S et al. Complex encounters: nanoparticles in whole blood and their uptake into different types of white blood cells. Nanomedicine 8(5), 699–713 (2013).
  Medline CASGoogle Scholar
• 20 Solmaz SR, Chauhan R, Blobel G, Melčák I. Molecular architecture of the transport channel of the nuclear pore complex. Cell 147(3), 590–602 (2011).
  Medline CASGoogle Scholar
• 21 Feldherr CM, Lanford RE, Akin D. Signal-mediated nuclear transport in simian virus 40-transformed cells is regulated by large tumor antigen. Proc. Natl Acad. Sci. USA 89(22), 11002–11005 (1992).
  Medline CASGoogle Scholar
• 22 De La Fuente JM, Berry CC. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug. Chem. 16(5), 1176–1180 (2005).
  Medline CASGoogle Scholar
• 23 Syed S, Zubair A, Frieri M. Immune response to nanomaterials: Implications for medicine and literature review. Curr. Allergy Asthma Rep. 13(1), 50–57 (2013).
  Medline CASGoogle Scholar
• 24 Bresee J, Bond CM, Worthington RJ et al. Nanoscale structure-activity relationships, mode of action, and biocompatibility of gold nanoparticle antibiotics. J. Am. Chem. Soc. 136(14), 5295–5300 (2014).
  Medline CASGoogle Scholar
• 25 Ryan JA, Overton KW, Speight ME et al. Cellular uptake of gold nanoparticles passivated with BSA-SV40 large T antigen conjugates. Anal. Chem. 79(23), 9150–9159 (2007).
  Medline CASGoogle Scholar
• 26 Tkachenko AG, Xie H, Liu Y et al. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 15(3), 482–490 (2004).
  Medline CASGoogle Scholar
• 27 Bender AR, Von Briesen H, Kreuter J, Duncan IB, Rübsamen-Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40(6), 1467–1471 (1996).
  Medline CASGoogle Scholar
• 28 Shah L, Amiji M. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/aids. Pharm. Res. 23(11), 2638–2645 (2006).
  Medline CASGoogle Scholar
• 29 Chattopadhyay N, Zastre J, Wong H-L, Wu X, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 25(10), 2262–2271 (2008).
  Medline CASGoogle Scholar
• 30 Shiang Y-C, Ou C-M, Chen S-J et al. Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles. Nanoscale 5(7), 2756–2764 (2013).
  Medline CASGoogle Scholar
• 31 Di Gianvincenzo P, Marradi M, Martínez-Ávila OM, Bedoya LM, Alcamí J, Penadés S. Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorg. Med. Chem. Lett. 20(9), 2718–2721 (2010).
  Medline CASGoogle Scholar
• 32 Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect. Dis. 13(11), 976–986 (2013).
  MedlineGoogle Scholar
• 33 Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Curr. Opin. HIV AIDS 9(6), 552–558 (2014).
  Medline CASGoogle Scholar
• 34 De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29(12), 1912–1919 (2008).
  Medline CASGoogle Scholar
• 35 Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf. B Biointerfaces 66(2), 274–280 (2008).
  Medline CASGoogle Scholar
• 36 Yim YS, Choi JS, Kim GT et al. A facile approach for the delivery of inorganic nanoparticles into the brain by passing through the blood-brain barrier (bbb). Chem. Commun. (Camb). 48(1), 61–63 (2012).
  Medline CASGoogle Scholar
• 37 Weiss CK, Kohnle MV, Landfester K et al. The first step into the brain: uptake of NIO-PBCA nanoparticles by endothelial cells in vitro and in vivo, and direct evidence for their blood-brain barrier permeation. ChemMedChem. 3(9), 1395–1403 (2008).
  Medline CASGoogle Scholar
• 38 Simpson CA, Agrawal AC, Balinski A, Harkness KM, Cliffel DE. Short-chain PEG mixed monolayer protected gold clusters increase clearance and red blood cell counts. ACS nano 5(5), 3577–3584 (2011).
  Medline CASGoogle Scholar
• 39 De Boer AG, Gaillard PJ. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 47, 323–355 (2007).
  Medline CASGoogle Scholar
• 40 Rapoport SI, Ohno K, Fredericks WR, Pettigrew KD. Regional cerebrovascular permeability to [14c]sucrose after osmotic opening of the blood-brain barrier. Brain Res. 150(3), 653–657 (1978).
  Medline CASGoogle Scholar
• 41 Etame AB, Diaz RJ, O'reilly MA et al. Enhanced delivery of gold nanoparticles with therapeutic potential into the brain using MRI-guided focused ultrasound. Nanomedicine 8(7), 1133–1142 (2012).
  Medline CASGoogle Scholar